市場調査レポート：世界の閉経後骨粗鬆症治療薬市場（～2028年）：経口、皮下注射、静脈注射、その他

• 英文タイトル：Global Post Menopausal Osteoporosis Drug Market Insights, Forecast to 2028

Global Post Menopausal Osteoporosis Drug Market Insights, Forecast to 2028「世界の閉経後骨粗鬆症治療薬市場（～2028年）：経口、皮下注射、静脈注射、その他」（市場規模、市場予測）調査レポートです。

• レポートコード：MRC2Q12-19348
• 出版社/出版日：QYResearch / 2022年12月
• レポート形態：英文、PDF、114ページ
• 納品方法：Eメール（納期：3営業日）
• 産業分類：医薬品＆医療

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、閉経後骨粗鬆症治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
閉経後骨粗鬆症治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
閉経後骨粗鬆症治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
閉経後骨粗鬆症治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までの閉経後骨粗鬆症治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の閉経後骨粗鬆症治療薬の売上および2028年までの予測に焦点を当てています。

閉経後骨粗鬆症治療薬のグローバル主要企業には、Amgen Inc、Ipsen SA、Aryogen Pharmed Co、Lupin Ltd、Celltrion Inc、Clayton Biotechnologies Inc、Hualan Biological Engineering Inc、Fresenius Kabi SwissBioSim GmbH、Genor BioPharma Co Ltd、InSight Biopharmaceuticals Ltd、Eden Biologics Inc、Enteris BioPharma Inc、Ablynx NV、Hengenix Biotech Inc、Luye Pharma Group Ltd、Intas Pharmaceuticals Ltd、Metabolab Inc、Jiangsu Hansoh Pharmaceutical Group Co Ltd、Jiangsu T-mab BioPharma Co Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

閉経後骨粗鬆症治療薬市場は、タイプとアプリケーションによって区分されます。世界の閉経後骨粗鬆症治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
経口、皮下注射、静脈注射、その他

【アプリケーション別セグメント】
病院、クリニック、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 閉経後骨粗鬆症治療薬製品概要
- タイプ別市場（経口、皮下注射、静脈注射、その他）
- アプリケーション別市場（病院、クリニック、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の閉経後骨粗鬆症治療薬販売量予測2017-2028
- 世界の閉経後骨粗鬆症治療薬売上予測2017-2028
- 閉経後骨粗鬆症治療薬の地域別販売量
- 閉経後骨粗鬆症治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別閉経後骨粗鬆症治療薬販売量
- 主要メーカー別閉経後骨粗鬆症治療薬売上
- 主要メーカー別閉経後骨粗鬆症治療薬価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模（経口、皮下注射、静脈注射、その他）
- 閉経後骨粗鬆症治療薬のタイプ別販売量
- 閉経後骨粗鬆症治療薬のタイプ別売上
- 閉経後骨粗鬆症治療薬のタイプ別価格
・アプリケーション別市場規模（病院、クリニック、その他）
- 閉経後骨粗鬆症治療薬のアプリケーション別販売量
- 閉経後骨粗鬆症治療薬のアプリケーション別売上
- 閉経後骨粗鬆症治療薬のアプリケーション別価格
・北米市場
- 北米の閉経後骨粗鬆症治療薬市場規模（タイプ別、アプリケーション別）
- 主要国別の閉経後骨粗鬆症治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの閉経後骨粗鬆症治療薬市場規模（タイプ別、アプリケーション別）
- 主要国別の閉経後骨粗鬆症治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の閉経後骨粗鬆症治療薬市場規模（タイプ別、アプリケーション別）
- 主要国別の閉経後骨粗鬆症治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の閉経後骨粗鬆症治療薬市場規模（タイプ別、アプリケーション別）
- 主要国別の閉経後骨粗鬆症治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの閉経後骨粗鬆症治療薬市場規模（タイプ別、アプリケーション別）
- 主要国別の閉経後骨粗鬆症治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Amgen Inc、Ipsen SA、Aryogen Pharmed Co、Lupin Ltd、Celltrion Inc、Clayton Biotechnologies Inc、Hualan Biological Engineering Inc、Fresenius Kabi SwissBioSim GmbH、Genor BioPharma Co Ltd、InSight Biopharmaceuticals Ltd、Eden Biologics Inc、Enteris BioPharma Inc、Ablynx NV、Hengenix Biotech Inc、Luye Pharma Group Ltd、Intas Pharmaceuticals Ltd、Metabolab Inc、Jiangsu Hansoh Pharmaceutical Group Co Ltd、Jiangsu T-mab BioPharma Co Ltd
・産業チェーン及び販売チャネル分析
- 閉経後骨粗鬆症治療薬の産業チェーン分析
- 閉経後骨粗鬆症治療薬の原材料
- 閉経後骨粗鬆症治療薬の生産プロセス
- 閉経後骨粗鬆症治療薬の販売及びマーケティング
- 閉経後骨粗鬆症治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 閉経後骨粗鬆症治療薬の産業動向
- 閉経後骨粗鬆症治療薬のマーケットドライバー
- 閉経後骨粗鬆症治療薬の課題
- 閉経後骨粗鬆症治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Post Menopausal Osteoporosis Drug Market
The global Post Menopausal Osteoporosis Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Oral accounting for % of the Post Menopausal Osteoporosis Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Post Menopausal Osteoporosis Drug market size is valued at US$ million in 2021, while the North America and Europe Post Menopausal Osteoporosis Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Post Menopausal Osteoporosis Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Post Menopausal Osteoporosis Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Post Menopausal Osteoporosis Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Post Menopausal Osteoporosis Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Post Menopausal Osteoporosis Drug market.
Global Post Menopausal Osteoporosis Drug Scope and Market Size
Post Menopausal Osteoporosis Drug market is segmented by players, region (country), by Way of Medication and by Application. Players, stakeholders, and other participants in the global Post Menopausal Osteoporosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Way of Medication and by Application for the period 2017-2028.
Segment by Way of Medication
Oral
Subcutaneous
Intravenous Injection
Others
Segment by Application
Hospitals
Clinics
Others
By Company
Amgen Inc
Ipsen SA
Aryogen Pharmed Co
Lupin Ltd
Celltrion Inc
Clayton Biotechnologies Inc
Hualan Biological Engineering Inc
Fresenius Kabi SwissBioSim GmbH
Genor BioPharma Co Ltd
InSight Biopharmaceuticals Ltd
Eden Biologics Inc
Enteris BioPharma Inc
Ablynx NV
Hengenix Biotech Inc
Luye Pharma Group Ltd
Intas Pharmaceuticals Ltd
Metabolab Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu T-mab BioPharma Co Ltd
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Way of Medication
1.2.1 Global Post Menopausal Osteoporosis Drug Market Size Growth Rate by Way of Medication, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Subcutaneous
1.2.4 Intravenous Injection
1.2.5 Others
1.3 Market by Application
1.3.1 Global Post Menopausal Osteoporosis Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Post Menopausal Osteoporosis Drug Market Perspective (2017-2028)
2.2 Post Menopausal Osteoporosis Drug Growth Trends by Region
2.2.1 Post Menopausal Osteoporosis Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Post Menopausal Osteoporosis Drug Historic Market Size by Region (2017-2022)
2.2.3 Post Menopausal Osteoporosis Drug Forecasted Market Size by Region (2023-2028)
2.3 Post Menopausal Osteoporosis Drug Market Dynamics
2.3.1 Post Menopausal Osteoporosis Drug Industry Trends
2.3.2 Post Menopausal Osteoporosis Drug Market Drivers
2.3.3 Post Menopausal Osteoporosis Drug Market Challenges
2.3.4 Post Menopausal Osteoporosis Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Post Menopausal Osteoporosis Drug Players by Revenue
3.1.1 Global Top Post Menopausal Osteoporosis Drug Players by Revenue (2017-2022)
3.1.2 Global Post Menopausal Osteoporosis Drug Revenue Market Share by Players (2017-2022)
3.2 Global Post Menopausal Osteoporosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Post Menopausal Osteoporosis Drug Revenue
3.4 Global Post Menopausal Osteoporosis Drug Market Concentration Ratio
3.4.1 Global Post Menopausal Osteoporosis Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Post Menopausal Osteoporosis Drug Revenue in 2021
3.5 Post Menopausal Osteoporosis Drug Key Players Head office and Area Served
3.6 Key Players Post Menopausal Osteoporosis Drug Product Solution and Service
3.7 Date of Enter into Post Menopausal Osteoporosis Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Post Menopausal Osteoporosis Drug Breakdown Data by Way of Medication
4.1 Global Post Menopausal Osteoporosis Drug Historic Market Size by Way of Medication (2017-2022)
4.2 Global Post Menopausal Osteoporosis Drug Forecasted Market Size by Way of Medication (2023-2028)
5 Post Menopausal Osteoporosis Drug Breakdown Data by Application
5.1 Global Post Menopausal Osteoporosis Drug Historic Market Size by Application (2017-2022)
5.2 Global Post Menopausal Osteoporosis Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Post Menopausal Osteoporosis Drug Market Size (2017-2028)
6.2 North America Post Menopausal Osteoporosis Drug Market Size by Way of Medication
6.2.1 North America Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2017-2022)
6.2.2 North America Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2023-2028)
6.2.3 North America Post Menopausal Osteoporosis Drug Market Share by Way of Medication (2017-2028)
6.3 North America Post Menopausal Osteoporosis Drug Market Size by Application
6.3.1 North America Post Menopausal Osteoporosis Drug Market Size by Application (2017-2022)
6.3.2 North America Post Menopausal Osteoporosis Drug Market Size by Application (2023-2028)
6.3.3 North America Post Menopausal Osteoporosis Drug Market Share by Application (2017-2028)
6.4 North America Post Menopausal Osteoporosis Drug Market Size by Country
6.4.1 North America Post Menopausal Osteoporosis Drug Market Size by Country (2017-2022)
6.4.2 North America Post Menopausal Osteoporosis Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Post Menopausal Osteoporosis Drug Market Size (2017-2028)
7.2 Europe Post Menopausal Osteoporosis Drug Market Size by Way of Medication
7.2.1 Europe Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2017-2022)
7.2.2 Europe Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2023-2028)
7.2.3 Europe Post Menopausal Osteoporosis Drug Market Share by Way of Medication (2017-2028)
7.3 Europe Post Menopausal Osteoporosis Drug Market Size by Application
7.3.1 Europe Post Menopausal Osteoporosis Drug Market Size by Application (2017-2022)
7.3.2 Europe Post Menopausal Osteoporosis Drug Market Size by Application (2023-2028)
7.3.3 Europe Post Menopausal Osteoporosis Drug Market Share by Application (2017-2028)
7.4 Europe Post Menopausal Osteoporosis Drug Market Size by Country
7.4.1 Europe Post Menopausal Osteoporosis Drug Market Size by Country (2017-2022)
7.4.2 Europe Post Menopausal Osteoporosis Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size (2017-2028)
8.2 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Way of Medication
8.2.1 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2017-2022)
8.2.2 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2023-2028)
8.2.3 Asia-Pacific Post Menopausal Osteoporosis Drug Market Share by Way of Medication (2017-2028)
8.3 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Application
8.3.1 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Post Menopausal Osteoporosis Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Region
8.4.1 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Post Menopausal Osteoporosis Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Post Menopausal Osteoporosis Drug Market Size (2017-2028)
9.2 Latin America Post Menopausal Osteoporosis Drug Market Size by Way of Medication
9.2.1 Latin America Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2017-2022)
9.2.2 Latin America Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2023-2028)
9.2.3 Latin America Post Menopausal Osteoporosis Drug Market Share by Way of Medication (2017-2028)
9.3 Latin America Post Menopausal Osteoporosis Drug Market Size by Application
9.3.1 Latin America Post Menopausal Osteoporosis Drug Market Size by Application (2017-2022)
9.3.2 Latin America Post Menopausal Osteoporosis Drug Market Size by Application (2023-2028)
9.3.3 Latin America Post Menopausal Osteoporosis Drug Market Share by Application (2017-2028)
9.4 Latin America Post Menopausal Osteoporosis Drug Market Size by Country
9.4.1 Latin America Post Menopausal Osteoporosis Drug Market Size by Country (2017-2022)
9.4.2 Latin America Post Menopausal Osteoporosis Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size (2017-2028)
10.2 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Way of Medication
10.2.1 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2017-2022)
10.2.2 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Way of Medication (2023-2028)
10.2.3 Middle East & Africa Post Menopausal Osteoporosis Drug Market Share by Way of Medication (2017-2028)
10.3 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Application
10.3.1 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Post Menopausal Osteoporosis Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Country
10.4.1 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Post Menopausal Osteoporosis Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amgen Inc
11.1.1 Amgen Inc Company Details
11.1.2 Amgen Inc Business Overview
11.1.3 Amgen Inc Post Menopausal Osteoporosis Drug Introduction
11.1.4 Amgen Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.1.5 Amgen Inc Recent Developments
11.2 Ipsen SA
11.2.1 Ipsen SA Company Details
11.2.2 Ipsen SA Business Overview
11.2.3 Ipsen SA Post Menopausal Osteoporosis Drug Introduction
11.2.4 Ipsen SA Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.2.5 Ipsen SA Recent Developments
11.3 Aryogen Pharmed Co
11.3.1 Aryogen Pharmed Co Company Details
11.3.2 Aryogen Pharmed Co Business Overview
11.3.3 Aryogen Pharmed Co Post Menopausal Osteoporosis Drug Introduction
11.3.4 Aryogen Pharmed Co Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.3.5 Aryogen Pharmed Co Recent Developments
11.4 Lupin Ltd
11.4.1 Lupin Ltd Company Details
11.4.2 Lupin Ltd Business Overview
11.4.3 Lupin Ltd Post Menopausal Osteoporosis Drug Introduction
11.4.4 Lupin Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.4.5 Lupin Ltd Recent Developments
11.5 Celltrion Inc
11.5.1 Celltrion Inc Company Details
11.5.2 Celltrion Inc Business Overview
11.5.3 Celltrion Inc Post Menopausal Osteoporosis Drug Introduction
11.5.4 Celltrion Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.5.5 Celltrion Inc Recent Developments
11.6 Clayton Biotechnologies Inc
11.6.1 Clayton Biotechnologies Inc Company Details
11.6.2 Clayton Biotechnologies Inc Business Overview
11.6.3 Clayton Biotechnologies Inc Post Menopausal Osteoporosis Drug Introduction
11.6.4 Clayton Biotechnologies Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.6.5 Clayton Biotechnologies Inc Recent Developments
11.7 Hualan Biological Engineering Inc
11.7.1 Hualan Biological Engineering Inc Company Details
11.7.2 Hualan Biological Engineering Inc Business Overview
11.7.3 Hualan Biological Engineering Inc Post Menopausal Osteoporosis Drug Introduction
11.7.4 Hualan Biological Engineering Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.7.5 Hualan Biological Engineering Inc Recent Developments
11.8 Fresenius Kabi SwissBioSim GmbH
11.8.1 Fresenius Kabi SwissBioSim GmbH Company Details
11.8.2 Fresenius Kabi SwissBioSim GmbH Business Overview
11.8.3 Fresenius Kabi SwissBioSim GmbH Post Menopausal Osteoporosis Drug Introduction
11.8.4 Fresenius Kabi SwissBioSim GmbH Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.8.5 Fresenius Kabi SwissBioSim GmbH Recent Developments
11.9 Genor BioPharma Co Ltd
11.9.1 Genor BioPharma Co Ltd Company Details
11.9.2 Genor BioPharma Co Ltd Business Overview
11.9.3 Genor BioPharma Co Ltd Post Menopausal Osteoporosis Drug Introduction
11.9.4 Genor BioPharma Co Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.9.5 Genor BioPharma Co Ltd Recent Developments
11.10 InSight Biopharmaceuticals Ltd
11.10.1 InSight Biopharmaceuticals Ltd Company Details
11.10.2 InSight Biopharmaceuticals Ltd Business Overview
11.10.3 InSight Biopharmaceuticals Ltd Post Menopausal Osteoporosis Drug Introduction
11.10.4 InSight Biopharmaceuticals Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.10.5 InSight Biopharmaceuticals Ltd Recent Developments
11.11 Eden Biologics Inc
11.11.1 Eden Biologics Inc Company Details
11.11.2 Eden Biologics Inc Business Overview
11.11.3 Eden Biologics Inc Post Menopausal Osteoporosis Drug Introduction
11.11.4 Eden Biologics Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.11.5 Eden Biologics Inc Recent Developments
11.12 Enteris BioPharma Inc
11.12.1 Enteris BioPharma Inc Company Details
11.12.2 Enteris BioPharma Inc Business Overview
11.12.3 Enteris BioPharma Inc Post Menopausal Osteoporosis Drug Introduction
11.12.4 Enteris BioPharma Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.12.5 Enteris BioPharma Inc Recent Developments
11.13 Ablynx NV
11.13.1 Ablynx NV Company Details
11.13.2 Ablynx NV Business Overview
11.13.3 Ablynx NV Post Menopausal Osteoporosis Drug Introduction
11.13.4 Ablynx NV Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.13.5 Ablynx NV Recent Developments
11.14 Hengenix Biotech Inc
11.14.1 Hengenix Biotech Inc Company Details
11.14.2 Hengenix Biotech Inc Business Overview
11.14.3 Hengenix Biotech Inc Post Menopausal Osteoporosis Drug Introduction
11.14.4 Hengenix Biotech Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.14.5 Hengenix Biotech Inc Recent Developments
11.15 Luye Pharma Group Ltd
11.15.1 Luye Pharma Group Ltd Company Details
11.15.2 Luye Pharma Group Ltd Business Overview
11.15.3 Luye Pharma Group Ltd Post Menopausal Osteoporosis Drug Introduction
11.15.4 Luye Pharma Group Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.15.5 Luye Pharma Group Ltd Recent Developments
11.16 Intas Pharmaceuticals Ltd
11.16.1 Intas Pharmaceuticals Ltd Company Details
11.16.2 Intas Pharmaceuticals Ltd Business Overview
11.16.3 Intas Pharmaceuticals Ltd Post Menopausal Osteoporosis Drug Introduction
11.16.4 Intas Pharmaceuticals Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.16.5 Intas Pharmaceuticals Ltd Recent Developments
11.17 Metabolab Inc
11.17.1 Metabolab Inc Company Details
11.17.2 Metabolab Inc Business Overview
11.17.3 Metabolab Inc Post Menopausal Osteoporosis Drug Introduction
11.17.4 Metabolab Inc Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.17.5 Metabolab Inc Recent Developments
11.18 Jiangsu Hansoh Pharmaceutical Group Co Ltd
11.18.1 Jiangsu Hansoh Pharmaceutical Group Co Ltd Company Details
11.18.2 Jiangsu Hansoh Pharmaceutical Group Co Ltd Business Overview
11.18.3 Jiangsu Hansoh Pharmaceutical Group Co Ltd Post Menopausal Osteoporosis Drug Introduction
11.18.4 Jiangsu Hansoh Pharmaceutical Group Co Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.18.5 Jiangsu Hansoh Pharmaceutical Group Co Ltd Recent Developments
11.19 Jiangsu T-mab BioPharma Co Ltd
11.19.1 Jiangsu T-mab BioPharma Co Ltd Company Details
11.19.2 Jiangsu T-mab BioPharma Co Ltd Business Overview
11.19.3 Jiangsu T-mab BioPharma Co Ltd Post Menopausal Osteoporosis Drug Introduction
11.19.4 Jiangsu T-mab BioPharma Co Ltd Revenue in Post Menopausal Osteoporosis Drug Business (2017-2022)
11.19.5 Jiangsu T-mab BioPharma Co Ltd Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer